Applying degrader approaches to improve therapeutic window of CAR-T therapies for paediatric solid tumours

We will develop combinations in which drugs with degrader capability for controlling tumour growth will also synergistically regulate CAR expression or function in T-cells by serving as “ON” or “OFF” switches for the CARs. Several complementary conceptual approaches will be evaluated systematically. Our aim is to identify the combination of ON and OFF CAR-T switches and their regulatory drugs that optimally maintains constant CAR-T activity whilst maximally treating the tumour.

Contact 
Ronja van Berkum